China's NMPA accepts Laekna's NDA for afuresertib, advancing a novel anticancer drug toward potential approval in the world's second-largest pharmaceutical market
Executive summary: China's National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for LAE002 (afuresertib) from Laekna for review, as announced on August 11, 2026. The acceptance advances a promising anticancer drug toward potential approval in China, the world's second-largest pharmaceutical market, which could expand Laekna's commercial footprint and address unmet medical needs in oncology.
Who is involved: Laekna (2105.HK), China's National Medical Products Administration (NMPA), specifically its Center for Drug Evaluation (CDE).
Likely next: Substantive review by the NMPA, potentially leading to approval within 12-15 months if clinical data meets standards, followed by commercial launch planning in China.
Laekna (2105.HK) announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for LAE002 (afuresertib) for review. The drug is being developed for the treatment of patients with solid tumors, representing a significant step in Laekna's oncology pipeline. Acceptance by the NMPA's Center for Drug Evaluation (CDE) indicates the submission met basic administrative and quality requirements to proceed to substantive review. This milestone positions afuresertib for potential approval in China, where demand for innovative oncology therapies is growing rapidly.
What's next — scenarios
Fast-Track Approval Success (25%)
Significant revenue uplift and valuation re-rating for Laekna due to first-mover advantage in a niche oncology segment.
- NMPA grants 'Breakthrough Therapy Designation'
- Successful completion of Phase III clinical data review
Extended Review Cycle (50%)
Increased cash burn and delayed revenue realization, potentially requiring additional financing for the 2105.HK entity.
- NMPA issues 'Request for Supplementary Information'
- Regulatory delays in clinical data auditing
Rejection or Request for New Trials (25%)
Severe liquidity crisis and potential impairment of R&D assets on the balance sheet.
- NMPA issues a 'Refusal to Accept' or rejection notice
- Requirement for a large-scale, localized Phase III trial
What to watch
- NMPA official registry update regarding LAE002 status (next 60 days)
- Laekna's quarterly cash burn rate report (next 90 days)
- Competitor clinical trial milestones in the same solid tumor indications (next 90 days)
Timeline
- — New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration (PR Newswire)
Analysis — what this means
Likely next events
- NMPA substantive review completion expected by Q4 2027
- Potential approval decision by mid-2028 if review proceeds standardly
- Laekna may initiate China commercial readiness activities in late 2027
Sectors affected
- Oncology pharmaceuticals
- Biotechnology R&D
- China healthcare market
Regulatory implications
- NMPA acceptance triggers standard 12-15 month review timeline under China's drug approval framework
- Post-approval, Laekna must comply with NMPA pharmacovigilance and reporting requirements
- Any future label expansions would require supplemental applications to NMPA
Historical parallels
- Similar to Merck's Keytruda (pembrolizumab) NDA acceptance by NMPA in 2016, leading to approval in 2019
- Mirrors BeiGene's bruciteanib NDA acceptance in 2020 for hepatocellular carcinoma, approved in 2021